首页> 外文期刊>European journal of nuclear medicine >Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine
【24h】

Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine

机译:靶向细胞因子/趋化因子受体:分子核医学的挑战

获取原文
获取原文并翻译 | 示例
       

摘要

Radiolabelled cytokines and chemokines are a group of radiopharmaceuticals that, by highlighting in vivo the binding to specific high-affinity receptors expressed on selected cell populations, allow the molecular and functional characterisation of immune-mediated processes Recently, several authors have described the use of radiolabelled cytokines and chemokines not only for imaging of inflammation and infection, but also as an approach to study in vivo the biology of primary and meta-static cancer cells. The latter avenue of research has been pursued particularly to help oncologists in therapeutic decision making and to follow up the efficacy of new immune therapies. In this paper we describe the characteristics of cytokines and chemokines, focussing on their role as radiopharmaceuticals for the imaging of cancer cells in vivo, a new challenge for molecular nuclear medicine.
机译:放射性标记的细胞因子和趋化因子是一组放射性药物,它们通过在体内突出显示与选定细胞群上表达的特定高亲和力受体的结合,可以对免疫介导的过程进行分子和功能表征。最近,几位作者描述了放射性标记的用途细胞因子和趋化因子不仅用于炎症和感染的成像,而且还可以作为体内研究原发性和转移性癌细胞生物学的方法。尤其是追求后一种研究途径,以帮助肿瘤学家进行治疗决策并跟踪新的免疫疗法的功效。在本文中,我们描述了细胞因子和趋化因子的特征,着重介绍了它们作为放射药物在体内癌细胞成像中的作用,这是分子核医学的一项新挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号